RxDoctor Payments Data

William Springhart, MD

Urology · Greenville, SCNPI 1760479968

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $16,883 of the $19,924 with a category attached, or 84.7%. EDAP Technomed Inc accounts for 66.1% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $11,404, more than ten times the $141 reported in 2019. Among urology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,924in general payments, 2019–2025

Across 51 payments — averaging $390.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EDAP Technomed Inc$13K
  • Calyxo, Inc.$5K
  • Siemens Medical Solutions USA, Inc.$1K
  • Boston Scientific$198
  • Coloplast$167
  • Procept Biorobotics Corporation$137
  • plus $122 from 6 others
$49,862in research payments, 2019–2025

Across 20 payments — averaging $2493.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Calyxo, Inc.$50K

What the payments were for

  • Consulting fees$16,88385%
  • Travel & lodging$5803%
  • Food & beverage$2,46112%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,924 in reported general payments places this provider in the 90th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$188,546
Medicare patients
499
Services billed
2,909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron11$6,478
Finasteride358$3,829
Potassium Citrate ErPotassium Citrate81$3,350
Tamsulosin Hcl275$2,771
Alfuzosin Hcl ErAlfuzosin Hcl72$2,021
Bicalutamide16$275
Allopurinol25$141
Ciprofloxacin Hcl62$124
Hydrochlorothiazide18$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$19$6,47811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 196 urology providers in South Carolina.

Other urology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →